Group 1 - Aosaikang's product, Liraglutide tablets (brand name: Aoyixin), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] - Kanghong Pharmaceutical's product, Conbercept eye injection (brand name: Langmu), has also been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1]

Core Insights - The company 奥赛康 (002755.SZ) announced that its product 利厄替尼片 (brand name: 奥壹新) has been included in the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, as per the notification from the National Healthcare Security Administration and the Ministry of Human Resources and Social Security dated December 7, 2025 [1] Group 1 - 利厄替尼 is a third-generation EGFR TKI developed collaboratively by the Shanghai Institute of Materia Medica, the Guangzhou Institute of Biomedicine and Health, and 江苏奥赛康药业有限公司, specifically targeting EGFR mutation non-small cell lung cancer (NSCLC) [1] - The inclusion of 利厄替尼片 in the national medical insurance catalog is expected to enhance the product's accessibility, facilitating market promotion and positively impacting sales [1]